Sun Pharma ne ESMO Congress 2026 mein apne cancer drug UNLOXCYT ka naya data share kiya hai. **205** patients par hui study mein result kaafi positive rahe hain, jo company ke specialty medicine portfolio ko aur strong banata hai.
Trial ke naye figures kya kehte hain?
Sun Pharma ne CK-301-101 trial ka naya data table par rakha hai. Yeh study 205 patients par thi jinhe advanced skin cancer (aCSCC) tha. Sabse badi baat yeh hai ki drug ka asar 2.5 saal se zyada tak barkarar raha hai, aur complete response ka rate bhi improve hua hai.
Specialty Medicine par focus
UNLOXCYT company ke liye ek 'star' product hai, jise 2024 mein FDA se approval mila tha. Ab jo naya clinical data aaya hai, woh oncologists ke beech is drug ki credibility ko aur badhayega, khaaskar un patients ke liye jo surgery nahi kar sakte.
Trial ki highlights:
- Group 2 mein 34.4% ka complete response rate dikha.
- Progression-free survival 37.3 months tak pahunch gaya.
- Safety profile solid hai, sirf 2.9% serious cases report hue aur koi fatality nahi hui.
Company ab specialty drugs par focus kar rahi hai jahan margin zyada milta hai. Investors ab yeh watch kar rahe hain ki kaise yeh clinical validation aage chal kar revenue growth mein badalti hai.